Power3 Medical Products, Inc. (OTC.BB:PWRM) business focus is the development of commercial applications for their proprietary technologies. The scientific team is on the leading edge of the proteomics industry through their discovery of protein footprints, pathways, and mechanisms of disease. These discoveries are being used to develop screening and diagnostic tests for the early detection and treatment of disease. The protein biomarkers, drug targets, and diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer, neurodegenerative disease and drug resistance in cancer. The Company is in a strong competitive position with over 190 identified biomarkers and a state-of-the-art proteomics laboratory.

Every 72 seconds someone in America will develop Alzheimer’s. Current estimate that 5.1Million Americans have Alzheimer’s. Almost 10 Million Americans caring for Alzheimer’s disease or related dementia.

Prevalance of Parkinson's Disease: 1.5 million people (unreliable estimate) Undiagnosed prevalence of Parkinson's Disease: estimated 3-4 million people Undiagnosed prevalence rate: approx 1 in 90 or 1.10% or 3 million people in USA.

According to the World Health Organization, more than 1.2 million people will be diagnosed with breast cancer each year worldwide and over 500,000 will die from the disease.

Proteomics is the global study of protein expression, regulation, modification, and function in living systems for understanding how living systems use proteins.

**************************************************

MusclePharm Corporation (OTCBB:MSLP), one of the fastest growing nutritional supplement companies in the United States, announced it has reached an agreement to raise $1.4 million through a convertible promissory note and registration agreement with an accredited investor.

This capital raise, combined with the previously released fulfillment agreement with IVitals, further enhances the Company's overall financial strength for future long-term profitable growth. Management will continue to focus on the development, sales & marketing of MusclePharm's growing portfolio of nutritional supplement products.

Headquartered in Denver, Colorado, MusclePharm is a rapidly expanding healthy life-style company that develops and manufactures a full line of NSF and scientifically approved, nutritional supplements that are 100% free of any banned substances. Based on years of research, MusclePharm products are created through an advanced six-stage research protocol involving the expertise of top nutritional scientists and field tested by more than 100 elite professional athletes from various sports including the NFL, MMA, and MLB. The Company's propriety and award winning products address all categories of an active lifestyle including muscle building, weight loss, and maintaining general fitness through a daily nutritional supplement regimen. MusclePharm is sold in over 120 countries and available in over 5,000 US retail outlets that include GNC, and Vitamin Shoppe, as well as over 100 online stores, including bodybuilding.com, Amazon and Vitacost.com.

**************************************************

SolarWinds, Inc. (NYSE:SWI) a leading provider of powerful and affordable IT management software for more than 97,000 companies worldwide, announced that it has established its Asia-Pacific headquarters in Brisbane, Australia.

SolarWinds provides powerful and affordable IT management software to more than 97,000 customers worldwide — from Fortune 500 enterprises to small businesses.

**************************************************

Brinker International Inc. (NYSE:EAT) has named Ian Baines Senior Vice President of Strategic Innovation for Brinker and Chili’s® Grill & Bar and promoted Carin Stutz to President of Brinker’s Global Business Development.

Brinker International, Inc. , is one of the world’s leading casual dining restaurant companies, serving more than one million guests daily. Founded in 1975 and based in Dallas, Texas, Brinker owns or franchises more than 1,500 restaurants in 29 countries.

**************************************************

OfficeMax Inc. (NYSE:OMX) a leader in office technology products and services, announced it is featuring the new Samsung Galaxy Tab™ from Sprint as one of the hottest holiday gifts of the season and the first mobile tablet for the Retailer. With its sleek design weighing in at just over 13.58 ounces, the Samsung Galaxy Tab offers users a unique navigation experience with a large seven-inch screen with Adobe® Flash® Player compatible; a front and rear-facing camera, SWYPE keyboard technology; and up to seven-hours of battery life. Samsung Galaxy Tab is available at all OfficeMax retail locations for $399 with a new line or eligible upgrade and two-year service agreement on a Sprint 3G Tablet Mobile Broadband plan.

OfficeMax Incorporated is a leader in both business-to-business office products solutions and retail office products. The OfficeMax mission is simple. We help our customers do their best work.

**************************************************************

********************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOmega.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://pennyomega.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (PWRM.OB).

Crown Equity Holdings Inc. (CRWE.OB) has received five thousand dollars and anticipates receiving another forty five thousand dollars in cash from a third party for 30 (thirty) days of advertising for MusclePharm Corporation (MSLP.OB)